Questcor Evaluating Development Strategies Following Acthar “Not Approvable” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
Competing firm Ovation tells “The Pink Sheet” DAILY it plans to submit its anticonvulsant vigabatrin for infantile spasms later this year.
You may also be interested in...
Acthar Will Test Switch From Off- To On-Label Use At Advisory Committee
Panel will decide whether re-analysis of trial data is enough to make Acthar treatment for infantile spasms on-label.
Acthar Will Test Switch From Off- To On-Label Use At Advisory Committee
Panel will decide whether re-analysis of trial data is enough to make Acthar treatment for infantile spasms on-label.
Questcor Acthar Gel Has Mid-’07 Action Date For Infantile Spasms, But Ovation To Seek Same Claim
Ovation plans to submit vigabatrin for the same indication in the coming weeks.